JP2019531296A - 眼疾患の処置方法 - Google Patents

眼疾患の処置方法 Download PDF

Info

Publication number
JP2019531296A
JP2019531296A JP2019517058A JP2019517058A JP2019531296A JP 2019531296 A JP2019531296 A JP 2019531296A JP 2019517058 A JP2019517058 A JP 2019517058A JP 2019517058 A JP2019517058 A JP 2019517058A JP 2019531296 A JP2019531296 A JP 2019531296A
Authority
JP
Japan
Prior art keywords
compound
diabetic
alkyl
bmx
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019517058A
Other languages
English (en)
Japanese (ja)
Inventor
ジョージ・チャン−イー・チョウ
チェン・チア−ナン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NatureWise Biotech and Medicals Corp
Original Assignee
NatureWise Biotech and Medicals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NatureWise Biotech and Medicals Corp filed Critical NatureWise Biotech and Medicals Corp
Publication of JP2019531296A publication Critical patent/JP2019531296A/ja
Priority to JP2021081095A priority Critical patent/JP2021138710A/ja
Priority to JP2023100597A priority patent/JP2023116748A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019517058A 2016-09-29 2017-09-29 眼疾患の処置方法 Withdrawn JP2019531296A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021081095A JP2021138710A (ja) 2016-09-29 2021-05-12 眼疾患の処置方法
JP2023100597A JP2023116748A (ja) 2016-09-29 2023-06-20 眼疾患の処置方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401725P 2016-09-29 2016-09-29
US62/401,725 2016-09-29
PCT/CN2017/104345 WO2018059543A1 (en) 2016-09-29 2017-09-29 Methods for treating ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021081095A Division JP2021138710A (ja) 2016-09-29 2021-05-12 眼疾患の処置方法

Publications (1)

Publication Number Publication Date
JP2019531296A true JP2019531296A (ja) 2019-10-31

Family

ID=61688114

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019517058A Withdrawn JP2019531296A (ja) 2016-09-29 2017-09-29 眼疾患の処置方法
JP2021081095A Pending JP2021138710A (ja) 2016-09-29 2021-05-12 眼疾患の処置方法
JP2023100597A Pending JP2023116748A (ja) 2016-09-29 2023-06-20 眼疾患の処置方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021081095A Pending JP2021138710A (ja) 2016-09-29 2021-05-12 眼疾患の処置方法
JP2023100597A Pending JP2023116748A (ja) 2016-09-29 2023-06-20 眼疾患の処置方法

Country Status (9)

Country Link
US (1) US11045435B2 (https=)
EP (1) EP3518913B1 (https=)
JP (3) JP2019531296A (https=)
KR (1) KR102341446B1 (https=)
CN (1) CN109789115A (https=)
CA (1) CA3038845C (https=)
MY (1) MY198731A (https=)
TW (1) TWI765917B (https=)
WO (1) WO2018059543A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
KR20240016352A (ko) * 2021-05-28 2024-02-06 노벨와이즈 파마슈티칼 코포레이션 약물-내성 암을 치료하기 위한 조성물 및 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
JP2007055903A (ja) * 2005-08-22 2007-03-08 Hirosaki Univ 眼血管血流障害改善剤
WO2008123395A1 (ja) * 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤
JP2011020999A (ja) * 2009-04-03 2011-02-03 Genshin Seigi Yakuhin Kofun Yugenkoshi ヒストン脱アセチル化酵素を阻害するためのシナミック化合物とその誘導体
JP2011513382A (ja) * 2008-03-03 2011-04-28 ファーマライト インコーポレイテッド 眼の刺激物質を用いる眼の眼球後血流の刺激

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CA2630174A1 (en) * 2007-05-02 2008-11-02 Mitchell Alan Winnik Loading quantum dots into thermo-responsive microgels by reversible transfer from organic solvents to water
EP2346827B1 (en) * 2008-08-27 2013-11-13 Leo Pharma A/S Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
ES2473792T3 (es) * 2009-04-03 2014-07-07 Naturewise Biotech & Medicals Corporation Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
EP2277387B1 (en) * 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
CN104080467B (zh) * 2011-05-09 2020-09-15 急速制药公司 整联蛋白受体拮抗剂及其使用方法
CA2946086A1 (en) * 2014-04-17 2015-10-22 Teraclon Idf, S.L. Recombinant monoclonal antibodies vnar neutralizing the vascular endothelial growth factor (vegf)
US9956254B2 (en) * 2015-02-26 2018-05-01 Naturewise Biotech & Medicals Corporation Extract of taiwanese propolis for treating ocular diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
JP2007055903A (ja) * 2005-08-22 2007-03-08 Hirosaki Univ 眼血管血流障害改善剤
WO2008123395A1 (ja) * 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤
JP2011513382A (ja) * 2008-03-03 2011-04-28 ファーマライト インコーポレイテッド 眼の刺激物質を用いる眼の眼球後血流の刺激
JP2011020999A (ja) * 2009-04-03 2011-02-03 Genshin Seigi Yakuhin Kofun Yugenkoshi ヒストン脱アセチル化酵素を阻害するためのシナミック化合物とその誘導体
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 51, JPN6020014054, 2010, pages 3639 - 3645, ISSN: 0004547334 *
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 18, no. 4, JPN6020014049, 2014, pages 646 - 655, ISSN: 0004547332 *
NEUROMOLECULAR MEDICINE, vol. 18, JPN6020014052, 21 January 2016 (2016-01-21), pages 134 - 145, ISSN: 0004547333 *
PLOS ONE, vol. Vol.10, No.3, e0120587, JPN6020014056, 2015, pages 1 - 32, ISSN: 0004547335 *
PLOS ONE, vol. Vol.11, No.9, e0162596, JPN6020014062, 12 September 2016 (2016-09-12), pages 1 - 16, ISSN: 0004547336 *

Also Published As

Publication number Publication date
KR20190045304A (ko) 2019-05-02
JP2021138710A (ja) 2021-09-16
CA3038845A1 (en) 2018-04-05
CA3038845C (en) 2022-04-19
US20180085329A1 (en) 2018-03-29
EP3518913A1 (en) 2019-08-07
TW201828933A (zh) 2018-08-16
EP3518913C0 (en) 2025-07-23
WO2018059543A1 (en) 2018-04-05
EP3518913A4 (en) 2020-05-27
US11045435B2 (en) 2021-06-29
CN109789115A (zh) 2019-05-21
MY198731A (en) 2023-09-20
KR102341446B1 (ko) 2021-12-21
TWI765917B (zh) 2022-06-01
JP2023116748A (ja) 2023-08-22
EP3518913B1 (en) 2025-07-23

Similar Documents

Publication Publication Date Title
Liang et al. Salidroside alleviates oxidative stress in dry eye disease by activating autophagy through AMPK-Sirt1 pathway
AU2011245384C1 (en) Formulations of quinones for the treatment of ophthalmic diseases
Wang et al. Melatonin ameliorates oxidative stress-mediated injuries through induction of HO-1 and restores autophagic flux in dry eye
AU2011245384B9 (en) Formulations of quinones for the treatment of ophthalmic diseases
Wang et al. Erythropoietin protects retinal pigment epithelial cells from oxidative damage
US20100273892A1 (en) Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
JP2023116748A (ja) 眼疾患の処置方法
JP2017538728A (ja) イオントフォレシスを用いた生物活性分子の眼内送達
JP2015519398A (ja) 治療用製剤および処置の方法
Akiyama et al. Edaravone prevents retinal degeneration in adult mice following optic nerve injury
Chen et al. Vitamin K1 alleviates retinal inflammation following acute ocular hypertension by modulating microglial ferroptosis
Hu et al. MDL800, a SIRT6 activator, mitigates neuroinflammation-induced retinal damage by modulating microglial M1/M2 polarization in experimental glaucoma
Bao et al. Methyl 3, 4-dihydroxybenzoate protects retina in a mouse model of acute ocular hypertension through multiple pathways
EP4138820A1 (en) Small molecules for treating age-related retinal diseases
HK40002019A (zh) 用於治疗眼疾的方法
CN112913775A (zh) 一种药物(调往诱导剂mnu)诱导自发性白内障的方法
CN119548509B (zh) 一种小分子化合物组合物及其应用
Santos Towards a new therapy for diabetic retinopathy: ras and berries
da Cruz Santos Towards a New Therapy for Diabetic Retinopathy: RAS and Berries
CN120884562A (zh) 载药聚合物、stat3抑制剂复合纳米颗粒及制备方法和在眼科药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190529

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210512

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210512

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210525

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210608

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210615

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210709

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210713

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20211005